TITLE: Inhibitory Effect of a Novel DNA Aptamer with Artificial Nucleic Bases for Von Willebrand Factor A1 Domain on Platelet Thrombosis FormationAmerican Society of Hematology
the American Society of Hematology, the 60th Annual Meeting and Exposition (December 1-4, 2018) in San Diego ,
CA Session Name: 332. Anti-thrombotic Therapy: Poster II
Date: Sunday, December 2, 2018 at 6PM PDT
Authors: Kazuya Sakai1, Hideo Yagi1, Masaki Hayakawa1, Tatsuhiko
Someya2, Kaori Harada2, and Masanori Matsumoto1 1. Department of
Blood Transfusion Medicine, Nara Medical University, Nara, Japan 2.
TAGCyx Biotechnologies Inc, Tokyo, Japan
The conference information will be found here.
Date: October 10th-12th 2018
Place: Pacifico Yokohama 1-1-1 Minato Mirai, Nishi-ku, Yokohama 220-0012, Japan
Conference details are found here.
the 80th Annual Meeting of the Japanese Society of Hematology
Date: October 13th at 9am
Oral presentation OS2-13A-1
Title: “Inhibitory effect of novel DNA aptamer for von Willebrand factor on platelet thrombosis formation”
Kazuya Sakai1, Hideo Yagi1, Masaki Hayakawa1, Kaori Harada2, Tatsuhiko Someya 2, Yoshihiro Fujimura3, Masanori Matsumoto1
1, Department of Blood Transfusion Medicine, Nara Medical University
2, TAGCyx Biotechnologies Inc.
3, Japanese Red Cross Kinki Block Blood Center
Please find the conference details here
TAGCyx has signed collaborative research agreement with HEALIOS K.K. (CEO: Hardy TS Kagimoto, MD, Head office: Tokyo, listed on Tokyo Stock Exchange Mothers Index: 4593), to generate TAGCyx’ innovative DNA aptamers, Xenoligo®.
Based on the terms of the agreement, TAGCyx will generate Xenoligo®, using its proprietary artificial nucleic acid base pair technology in order to contribute the development of HEALIOS’ regenerative medicine and cell therapeutics.
In return, TAGCyx will receive collaborative research fees as well as milestone payments upon successful generation of the aptamers.
Under the confidentiality of the agreement, further details of the research is not disclosed.
TAGCyx Biotechnologies Inc. (Tokyo, Japan) has raised 500 million JPY in Series B financing as of 24th April 2018, from four venture capital firms, the University of Tokyo Edge Capital Co., Ltd. (UTEC) (Tokyo), SMBC Venture Capital Co., Ltd. (Tokyo), UTokyo Innovation Platform Co., Ltd. (Tokyo) and Mizuho Capital Co., Ltd. (Tokyo).
20180427 Press Release（Eng)